What they were paid
ARROWHEAD PHARMACEUTICALS Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $80,000 | $340,684 | $0 | $0 | $420,684 |
| FY2024 | $80,000 | $380,833 | — | — | $460,833 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ARROWHEAD PHARMACEUTICALS, INC. DEF 14A filed January 27, 2026, accession 0000879407-26-000019, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025ARROWHEAD PHARMACEUTICALS pays directors a $80,000 cash retainer and $340,684 in RSUs.
Committees
FY2025 · as the proxy prints themNominating/Governance · Science & Technology Committee (Co-Chair) (Chair)
The rest of the ARROWHEAD PHARMACEUTICALS board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Christopher Anzalone | Chair of the Board | $0 |
| Douglas Ingram | Independent Director | $846,350 |
| Hongbo Lu | Independent Director | $420,684 |
| Mauro Ferrari | Independent Director | $420,684 |
| Michael S. Perry | Independent Director | $428,184 |
| Victoria Vakiener | Independent Director | $424,434 |
| William Waddill | Independent Director | $438,184 |
The full ARROWHEAD PHARMACEUTICALS compensation record
free company briefThis page is one director within ARROWHEAD PHARMACEUTICALS's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat